UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 2425, 2018

AVEXIS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-37693		90-1038273
(Commission File No.)		(IRS Employer Identification No.)

2275 Half Day Rd, Suite 200

Bannockburn, Illinois 60015

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (847) 572-8280

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01 Other Events.

On April 2425, 2018, AveXis, Inc. (the “Company”) issued a press release announcing that the ~~Company~~first ~~will~~patient ~~present~~has ~~initial~~been ~~results~~dosed ~~from~~in ~~its~~the ~~pivotal~~Company’s Phase 3 clinical trial of AVXS-101 for the treatment of pre-symptomatic spinal muscular atrophy (“SMA”) ~~Type~~Types 1, as2 ~~well~~and ~~as the 24-month follow-up data from its Phase 1 clinical trial of AVXS-101 for the treatment of SMA Type 1 at the 2018 Annual Meeting of the American Academy of Neurology~~3. The full text of the Company’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit
Number		Exhibit Description
99.1		Press Release, dated April 2425, 2018, titled “AveXis ~~Presents~~Announces ~~Initial~~First ~~Data~~Patient ~~from~~Dosed ~~Pivotal~~in ~~U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from~~ Phase 13 Trial of AVXS-101 in Pre-Symptomatic SMA ~~Type~~Types 1, at2 ~~the~~and ~~Annual Meeting of the American Academy of Neurology~~3.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 24, 2018	AVEXIS, INC.
Date: April 25, 2018	AVEXIS, INC.
	By:	/s/ Sean P. Nolan
		Sean P. Nolan
		President and Chief Executive Officer

Filing Compare · AveXis, Inc.